Here’s a test of whether your analyst does actual homework or just regurgitates press releases: ask them about Regeneron’s (REGN) development balance with Sanofi (SNY). I can almost guarantee the blank stares that usually follow. That obscure line item buried in the 10-Q filing dropped $253 million last quarter to $1.2 billion, which means Regeneron’s […]
Tag Archives: (MRK)
My barber Charlie has this uncanny ability to diagnose which of his clients are making money in the market just by watching how they tip. Last Thursday, while he was working his magic on what’s left of my hairline, he mentioned how his pharmaceutical rep clients have been tipping like oil sheiks lately. “Something big […]
Mad Hedge Biotech and Healthcare Letter August 21, 2025 Fiat Lux Featured Trade: (SLOW AND STEADY WINS) (MRK), (LLY)
Mad Hedge Biotech and Healthcare Letter July 8, 2025 Fiat Lux Featured Trade: (THIS BIOTECH ISN’T DEAD YET. IT’S JUST GETTING ITS SECOND WIND) (MRK), (JNJ), (PFE)
Let me let you in on a little Wall Street secret: Merck & Co. (MRK) is having what my grandmother used to call “a spell,” and it’s not the kind that ends with Mai Tais on a cruise ship. Down 18% year-to-date, Merck’s been standing quietly in the corner like the designated driver at an […]
Mad Hedge Biotech and Healthcare Letter May 29, 2025 Fiat Lux Featured Trade: (TIME FOR SOME RETAIL THERAPY) (MRNA), (MRK)
The other week, while hiking through the Marin Headlands with my old climbing partner from my Everest days, I got a call that reminded me why contrarian investing can be so profitable. My friend Janet, who runs a small biotech fund in Boston, was practically hyperventilating about Moderna (MRNA). Not because she was excited, mind […]
Mad Hedge Biotech and Healthcare Letter April 17, 2025 Fiat Lux Featured Trade: (THIS BIG PHARMA’S GRAND DIVORCE SHOWS PROMISE) (NVS), (SDZNY), (MRK), (RHHBY)
While most corporate breakups end with shareholders reaching for antacids, Novartis (NVS) investors are popping champagne instead. The Swiss pharmaceutical giant’s 2023 divorce from its generics business Sandoz (SDZNY) has transformed the company from a pharmaceutical conglomerate into a focused innovation machine – and the numbers would make even the most jaded among us whistle […]
Mad Hedge Biotech and Healthcare Letter April 10, 2025 Fiat Lux Featured Trade: (THE $5 BILLION SECRET I SPOTTED IN MY DOCTOR’S WAITING ROOM) (AMGN), (NVO), (LLY), (MRK), (REGN)